Treatment of Lung Cavities Caused by Infectious Organisms
Diagnostic Approach
- The Infectious Diseases Society of America recommends obtaining definitive microbiologic diagnosis before finalizing therapy, with CT scan with contrast enhancement being essential for proper evaluation of suspected cavitary pneumonia 1
- Blood cultures and respiratory specimens (BAL or protected specimen brush) should be obtained before initiating antimicrobial therapy, as recommended by the Infectious Diseases Society of America 3, 1
- For suspected fungal causes, serologic testing and galactomannan testing should be performed, according to the Infectious Diseases Society of America guidelines 1, 2
Bacterial Cavitary Pneumonia
- The American Thoracic Society recommends that Staphylococcus aureus infections require early and aggressive antimicrobial therapy, with treatment guided by susceptibility testing, particularly for MRSA 1
- For documented P. aeruginosa pneumonia, the Infectious Diseases Society of America recommends using an antipseudomonal β-lactam (piperacillin-tazobactam, ceftazidime, imipenem/cilastatin, meropenem, or cefepime) plus an aminoglycoside when local resistance patterns indicate suboptimal β-lactam activity 3, 4, 5
- High-dose trimethoprim-sulfamethoxazole (15-20 mg/kg/day of trimethoprim component) is the preferred regimen for Stenotrophomonas maltophilia, as recommended by the Infectious Diseases Society of America 3, 4, 5
Fungal Cavitary Pneumonia
- The Infectious Diseases Society of America recommends oral azole therapy with fluconazole 400 mg daily or itraconazole 200 mg twice daily as first-line treatment for coccidioidomycosis 6, 7, 2
- Treatment must be continued for at least 1 year, and often longer, with clinical response rates being approximately 55% after 8 months of treatment 6, 7, 8, 2
- Amphotericin B should be reserved for patients who do not respond to azoles, or for those with severe illness requiring intensive care management 6, 7, 8, 2
- Surgical intervention for coccidioidal cavities should be explored when cavities are persistently symptomatic despite antifungal treatment, or when cavities have been present for >2 years and symptoms recur when antifungal treatment is stopped 6, 7, 8
Monitoring and Follow-Up
- The Infectious Diseases Society of America recommends that response to antimicrobial treatment should be clinically assessed on a daily basis, with imaging studies to reassess treatment response generally not being ordered earlier than 7 days after starting treatment 4, 5, 2
- In patients with lack of clinical improvement, CT scan should be repeated after 7 days, with persisting fever, progressive or newly emerged infiltrates, and rising inflammatory parameters indicating need for repeated microbiological diagnostics and change in antimicrobial regimen 4, 5
- For fungal infections, repeat chest imaging should be performed approximately 4-6 weeks after initiation of treatment, with increasing volume of pulmonary infiltrates possibly occurring during the first week despite effective antifungal therapy 2
Common Complications and Pitfalls
- Fungal superinfections can occur within pre-existing bacterial cavities, forming fungus balls (mycetomas), and bacterial superinfection may occur in patients not responding to antifungal treatment 1, 6, 7, 8, 2
- Hemoptysis can range from mild to severe and life-threatening, and may require surgical intervention in severe cases 1, 2
- Cavity rupture can lead to pneumothorax or pyopneumothorax, with approximately one-third of ruptured coccidioidal cavities presenting with simple spontaneous pneumothorax 1, 6, 7, 8, 9